1. Targeted Cancer Therapeutics, LLC Investor Presentation

2. Table of Contents  Introduction  Technology  Efficacy  Safety  Market Size  Orphan Drug Status  Management  Valuation Analysis  Investment Opportunity  Use of Proceeds  Exit Strategy

3. Introduction  Targeted Cancer Therapeutics, LLC (“TCT”) is an early stage company that has developed an antibody to treat Pancreatic Cancer  Current treatment for Pancreatic Cancer does little to either alleviate patient suffering or reduce tumor size  TCT’s therapy has been clinically demonstrated to substantially reduce tumor size

4. Technology  CEACAM-6 is a tumor associated antigen (compound produced by tumors)  CEACAM-6 is overexpressed in 90% of all Pancreatic Cancer patients  The Anti-CEACAM-6 antibody reduces Pancreatic Cancer tumor cell vitality  This antibody binds itself to CEACAM-6, interferes with CEACAM-6’s function and causes “apoptosis” (cell death a process important in preventing tumor formation)

5. Efficacy of TCT’s CEACAM-6 Antibody

6. Therapy Safety  TCT’s Anti CEACAM-6 Antibody is a highly targeted therapy for treating Pancreatic Cancer  Highly targeted therapies are inherently less toxic than traditional chemotherapy  TCT’s antibody has been demonstrated to possess little toxic side effects as a result of specifically targeting a tumor associated antigen

7. Market Size GenderDiagnosedDeath Male22,09018,850 Female21,83018,540 Total43,92037,390 This table presents the prevalence rates of Pancreatic Cancer by gender within the United States. The Pancreatic Cancer market size is roughly 44,000 individuals with significant increases projected in the coming years. The Mortality Rate according to this data is 85%. This presents a massive unmet medical need that TCT is poised to fulfill with its Anti-CEACAM-6 antibody. TCT’s antibody is targeting several unmet medical needs: (1) Introduce a Pancreatic Cancer therapy that dramatically reduces the size of Pancreatic Cancer tumors thereby improving treating the disease and (2) Increasing the overall quality of life for Pancreatic Cancer patients. TCT’s antibody represents a significant improvement over existing Pancreatic Cancer treatment.

8. Market Size Race/EthnicityMaleFemale All Races13.8 per 100,000 men10.8 per 100,000 women White13.7 per 100,000 men10.6 per 100,000 women Black17.7 per 100,000 men14.4 per 100,000 women Asian/Pacific Islander10.5 per 100,000 men8.8 per 100,000 women American Indian11.5 per 100,000 men10.3 per 100,000 women Hispanic11.6 per 100,000 men10.3 per 100,000 women Incidence rates of Pancreatic Cancer for men and women in the United States. This table demonstrates the rates of Pancreatic Cancer among various gender groups within the United States. These numbers are expressed as percentages. For example, White Males accounted for 13.7% of Pancreatic Cancer cases in 2012. African American Males held the largest percentage of cases at roughly 18% of all cases.

9. Orphan Drug Status  “Orphan Drug” reduces the time to market which allows TCT to realize revenues sooner than most biotech's  “Orphan Drug” will increase TCT’s ability to deliver significant ROI for Series A investors  TCT will be applying for “Orphan Drug” status with the Food & Drug Administration for its Pancreatic Cancer Treatment  “Orphan Drug” status eliminates the requirement to conduct Phase 3 Clinical Trials

10. Management  Dr. Mahadevan, Phd/MD, Chief Scientific Officer, is a pioneer in the field of drug design and the study of pancreatic cancer. Dr. Mahadevan is a Professor of Medicine and the Director of the Phase I Program at the University of Arizona – Arizona Cancer Center. Dr. Mahadevan’s major area of clinical interest is in the treatment and management of patients with Pancreatic cancer, Breast cancer, Gastrointestinal Stromal Tumors (GIST), Myelodysplastic Syndromes (MDS) and non- Hodgkin’s lymphoma (NHL). He is one of very few physician-scientists in the US with a Ph.D. in protein crystallography, molecular modeling and drug design who is also board certified in medical oncology.

11. TCT Risk Adjusted Valuation

12. Investment Opportunity  TCT has been funded to date by the founders and close associates, but requires the following:  Round 1 funding of $2,500,000 (to be completed by the end of 2012)  Round 2 funding of $6,000,000 after IND approval (to be completed prior to the end of 2013)  Self sustaining thereafter!  TCT represents a unique investment opportunity that offers a 19% ROI in approximately 24 months  TCT’s funding requirement is so low due in part to: (1) Development costs have already been incurred; (2) Orphan Drug status so no Phase III trials and (3) TCT has the option of sub-licensing the product after Phase I trials

13. Use of Proceeds  TCT is anticipating the following use of proceeds following Round 1 financing:  Additional Toxicity Testing  IND Filing with the FDA  Manufacturing of the product in accordance with GMP standards

14. Exit Strategy TCT has two potential exit options (1) Out license the products to a large biotech or pharmaceutical company (2) Deliver product to market under accelerated time line generating significant cash flow then seek a larger pharmaceutical company interested in either acquiring TCT or licensing the product from TCT

15. Animal Toxicity Testing of Pancreatic Cancer Therapy (Q1-Q4) IND Filing/Approval for Pancreatic Cancer Therapy (Q4-Q6) Phase I Clinical Trials of Pancreatic Cancer Therapy (Q6-Q10) Milestones

16. Contact  If you have any additional questions or would like to discuss investing in TCT please contact Thomas Latino of Strategic Global Associates at 617-935-2588.